Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $329

BenzingaNov 1 21:46 · Ratings

Alnylam Pharmaceuticals Analyst Ratings

BenzingaNov 1 18:05 · Ratings

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest

BenzingaNov 1 03:45

Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500

BenzingaNov 1 03:23

Alnylam Pharmaceuticals Shares Are Trading Lower After the Company Reported Mixed Q3 Financial Results.

BenzingaOct 31 20:17

Alnylam Pharmaceuticals Reiterated 2024 Financial Guidance, Including Combined Net Product Revenues Of $1.575B-$1.65B

BenzingaOct 31 20:04